Labelling content management company Kallik has secured an undisclosed investment from Midven, through its Exceed Fund, to expand its footprint.
Staffordshire-based Kallik provides artwork generation services relating to the packaging industry and has customers including Estee Lauder, Integra and Unilever.
]Kallik will use the cash it has garnered to further invest in what it calls integrated sales, marketing and product communication programmes. It hopes to increase its footprint and market share in regulated global industries including life sciences, cosmetics and chemicals.
Carole Gleghorn, co-founder and CFO at Kallik, says that the business has come a long way since its early days in the print industry to its current status as a provider of labelling content management services.
She adds, ‘Together with some strategic industry partners we are expanding our reach into larger business opportunities and this investment from Midven will underpin those expansion opportunities and boost our sales and marketing outreach and impact.’
Midven manages five funds representing some £61m under management. Its £18.4 million Exceed Fund was established in December 2009 to invest in high growth businesses in the West Midlands. It became operational in March 2010 when LDC became an investor in the Fund.
More on Midven investments:
- Midven backs student services business BeGo
- Birmingham video firm receives Midven cash
- Fertility test business nets return investment from Midven’s Exceed Fund
Ian Fairclough, investment manager for Midven’s Exceed Fund, comments, ‘Kallik’s prospects have been burgeoning, and with the significant revenue already secured over the next two yeas, we see this as an opportunity to invest in a profitable organisation with a stable product offering.
‘The company continues to move forward with some significant client wins, and this investment enables the management team to move the organisation to the next stage with confidence.’
Midven’s last investment came earlier in February when it injected £3.5 million into Cytox, a blood biomaker.
